Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Antiviral Research

Volumn 153, Issue , 2018, Pages 85-94

  Delang, Leen ^a   Abdelnabi, Rana ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; RNA POLYMERASE; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BORNA DISEASE VIRUS; CHIKUNGUNYA VIRUS; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EBOLAVIRUS; ENTEROVIRUS A71; ENTEROVIRUS D68; FOOT AND MOUTH DISEASE VIRUS; HANTAVIRUS; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LASSA VIRUS; MARBURGVIRUS; MEASLES VIRUS; MURINE; NONHUMAN; PARAMYXOVIRINAE; PICHINDE VIRUS; POLIOMYELITIS VIRUS; POSITIVE-STRAND RNA VIRUS; PRIORITY JOURNAL; RABIES VIRUS; REVIEW; RHINOVIRUS; RIFT VALLEY FEVER VIRUS; RNA VIRUS; RNA VIRUS INFECTION; SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME; WEST NILE VIRUS; WESTERN EQUINE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS; ZIKA VIRUS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; TREATMENT OUTCOME;

AMIDES; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PYRAZINES; RNA VIRUS INFECTIONS; RNA VIRUSES; TREATMENT OUTCOME;

EID: 85044444590     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.03.003     Document Type: Review

References (76)

1. Abdelnabi, R., Jochmans, D., Verbeken, E., Neyts, J., Delang, L., Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. Antivir. Res., 2017 https://doi.org/10.1016/j.antiviral.2017.09.016.
2. Abdelnabi, R., Morais, A.T.S., De Leyssen, P., Imbert, I., Beaucourt, S., Blanc, H., Froeyen, M., Vignuzzi, M., Canard, B., Neyts, J., Delang, L., Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase. J. Virol., 91, 2017 e00487–17 https://doi.org/10.1128/JVI.00487-17.
3. Arias, A., Thorne, L., Goodfellow, I., Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife, 3, 2014, e03679 https://doi.org/10.7554/eLife.03679.
4. Bai, C.Q., Mu, J.S., Kargbo, D., Song Bin, Y., Niu, W.K., Nie, W.M., Kanu, A., Liu, W.W., Wang, Y.P., Dafae, F., Yan, T., Hu, Y., Deng, Y.Q., Lu, H.J., Yang, F., Zhang, X.G., Sun, Y., Cao, Y.X., Su, H.X., Sun, Y., Liu, Sen, W., Wang, C.Y., Qian, J., Liu, L., Wang, H., Tong, Y.G., Liu, Z.Y., Chen, Y.S., Wang, H.Q., Kargbo, B., Gao, G.F., Jiang, J.F., Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705) - Sierra Leone, 2014. Clin. Infect. Dis. 63 (2016), 1288–1294 https://doi.org/10.1093/cid/ciw571.
5. Bank, C., Renzette, N., Liu, P., Matuszewski, S., Shim, H., Foll, M., Bolon, D.N.A., Zeldovich, K.B., Kowalik, T.F., Finberg, R.W., Wang, J.P., Jensen, J.D., An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy. Evol. (N. Y) 70 (2016), 2470–2484 https://doi.org/10.1111/evo.13041.
6. Banyard, A.C., Mansfield, K.L., Wu, G., Selden, D., Thorne, L., Birch, C., Koraka, P., Osterhaus, A.D.M.E., Fooks, A.R., Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Vaccine, 2017 https://doi.org/10.1016/j.vaccine.2017.10.109.
7. Baranovich, T., Wong, S.-S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Govorkova, E.A., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87 (2013), 3741–3751 https://doi.org/10.1128/JVI.02346-12.
8. Baz, M., Goyette, N., Griffin, B.D., Kobinger, G.P., Boivin, G., In vitro susceptibility of geographically and temporally distinct zika viruses to favipiravir and ribavirin. Antivir. Ther., 2017 https://doi.org/10.3851/IMP3180.
9. Bixler, S., Bocan, T., Wells, J.K.W., Van Tongeren, S., Dong, L., Lackemeyer, N., Donnelly, G., Cazares, L., Nuss, J., Soloveva, V., Koistinen, K., Welch, L., Epstein, C., Liang, L., Giesing, D., Lenk, R., Bavari, S., Warren, T., Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir. Res.(17), 2017, S0166–S3542, 10.1016/j.antivir 30737-4.
10. Bixler, S., Bocan, T.M., Wells, J., Wetzel, K., Van Tongeren, S., Lackemeyer, N., Donnelly, G., Cazares, L., Soloveva, V., Welch, L., Epstein, C., Liang, L.-F., Giesing, D., Lenk, R., Bavari, S., Warren, T.K., Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antivir. Res., 2017 https://doi.org/10.1016/j.antiviral.2017.12.020.
11. Bruenn, J.A., A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Res. 31 (2003), 1821–1829 https://doi.org/10.1093/nar/gkg277.
12. Buys, K.K., Jung, K.H., Smee, D.F., Furuta, Y., Gowen, B.B., Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir. Chem. Chemother. 21 (2011), 193–200 https://doi.org/10.3851/IMP1729.
13. Cai, L., Sun, Y., Song, Y., Xu, L., Bei, Z., Zhang, D., Dou, Y., Wang, H., Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch. Virol. 162 (2017), 2847–2853 https://doi.org/10.1007/s00705-017-3436-8.
14. Daikoku, T., Yoshida, Y., Okuda, T., Shiraki, K., Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J. Pharmacol. Sci. 126 (2014), 281–284 https://doi.org/10.1254/jphs.14156SC.
15. De Ávila, A.I., Gallego, I., Soria, M.E., Gregori, J., Quer, J., Ignacio Esteban, J., Rice, C.M., Domingo, E., Perales, C., Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One, 11, 2016 https://doi.org/10.1371/journal.pone.0164691.
16. de Avila, A.I., Moreno, E., Perales, C., Domingo, E., Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus Res. 233 (2017), 105–112 https://doi.org/10.1016/j.virusres.2017.03.014.
17. De Vleeschauwer, A.R., Lefebvre, D.J., Willems, T., Paul, G., Billiet, A., Murao, L.E., Neyts, J., Goris, N., De Clercq, K., A refined Guinea pig model of foot-and-mouth disease virus infection for assessing the efficacy of antiviral compounds. Transbound. Emerg. Dis. 63 (2016), e205–e212 https://doi.org/10.1111/tbed.12255.
18. Delang, L., Segura Guerrero, N., Tas, A., Quérat, G., Pastorino, B., Froeyen, M., Dallmeier, K., Jochmans, D., Herdewijn, P., Bello, F., Snijder, E.J., de Lamballerie, X., Martina, B., Neyts, J., van Hemert, M.J., Leyssen, P., Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J. Antimicrob. Chemother. 69 (2014), 2770–2784 https://doi.org/10.1093/jac/dku209.
19. Delang, L., Yen, P.-S., Vazeille, M., Failloux, A.-B., Can antiviral drug-resistant chikungunya viruses be transmitted by mosquito vectors?. International Conference on Antiviral Research, 2017.
20. Escribano-Romero, E., De Oya, N.J., Domingo, E., Saiza, J.C., Extinction of west nile virus by favipiravir through lethal mutagenesis. Antimicrob. Agents Chemother., 61, 2017 https://doi.org/10.1128/AAC.01400-17.
21. Furuta, Y., Komeno, T., Nakamura, T., Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 93 (2017), 449–463 https://doi.org/10.2183/pjab.93.027.
22. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K., In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46 (2002), 977–981 https://doi.org/10.1128/AAC.46.4.977-981.2002.
23. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K., Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005), 981–986 https://doi.org/10.1128/AAC.49.3.981-986.2005.
24. Gowen, B.B., Juelich, T.L., Sefing, E.J., Brasel, T., Smith, J.K., Zhang, L., Tigabu, B., Hill, T.E., Yun, T., Pietzsch, C., Furuta, Y., Freiberg, A.N., Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a Guinea pig model of Argentine hemorrhagic fever. PLoS Negl. Trop. Dis., 7, 2013 https://doi.org/10.1371/journal.pntd.0002614.
25. Gowen, B.B., Sefing, E.J., Westover, J.B., Smee, D.F., Hagloch, J., Furuta, Y., Hall, J.O., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antivir. Res. 121 (2015), 132–137 https://doi.org/10.1016/j.antiviral.2015.07.003.
26. Gowen, B.B., Westover, J.B., Miao, J., Van Wettere, A.J., Rigas, J.D., Hickerson, B.T., Jung, K.-H., Li, R., Conrad, B.L., Nielson, S., Furuta, Y., Wang, Z., Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir. J. Virol. 91 (2017), 1–12 https://doi.org/10.1128/JVI.01942-16.
27. Gowen, B.B., Westover, J.B., Sefing, E.J., Van Wettere, A.J., Bailey, K.W., Wandersee, L., Komeno, T., Furuta, Y., Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antivir. Res. 145 (2017), 131–135 https://doi.org/10.1016/j.antiviral.2017.07.019.
28. Gowen, B.B., Wong, M.-H., Jung, K.-H., Sanders, A.B., Mendenhall, M., Bailey, K.W., Furuta, Y., Sidwell, R.W., In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51 (2007), 3168–3176 https://doi.org/10.1128/AAC.00356-07.
29. Hartmann, T., Terao, M., Garattini, E., Teutloff, C., Alfaro, J.F., Jones, J.P., Leimkühler, S., The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab. Dispos. 40 (2012), 856–864 https://doi.org/10.1124/dmd.111.043828.
30. Jin, Z., Kinkade, A., Behera, I., Chaudhuri, S., Tucker, K., Dyatkina, N., Rajwanshi, V.K., Wang, G., Jekle, A., Smith, D.B., Beigelman, L., Symons, J.A., Deval, J., Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antivir. Res. 143 (2017), 151–161 https://doi.org/10.1016/j.antiviral.2017.04.005.
31. Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5’-triphosphate towards influenza A virus polymerase. PLoS One, 8, 2013, e68347 https://doi.org/10.1371/journal.pone.0068347.
32. Jin, Z., Tucker, K., Lin, X., Kao, C.C., Shaw, K., Tan, H., Symons, J., Behera, I., Rajwanshi, V.K., Dyatkina, N., Wang, G., Beigelman, L., Deval, J., Biochemical evaluation of the inhibition properties of favipiravir and 2’-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob. Agents Chemother. 59 (2015), 7504–7516 https://doi.org/10.1128/AAC.01391-15.
33. Jochmans, D., Van Nieuwkoop, S., Smits, S.L., Neyts, J., Fouchier, R.A.M., Van Den Hoogen, B.G., Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrob. Agents Chemother. 60 (2016), 4620–4629 https://doi.org/10.1128/AAC.00709-16.
34. Julander, J.G., Shafer, K., Smee, D.F., Morrey, J.D., Furuta, Y., Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53 (2009), 202–209 https://doi.org/10.1128/AAC.01074-08.
35. Julander, J.G., Smee, D.F., Morrey, J.D., Furuta, Y., Effect of T-705 treatment on western equine encephalitis in a mouse model. Antivir. Res. 82 (2009), 169–171 https://doi.org/10.1016/j.antiviral.2009.02.201.
36. Kim, J.-A., Seong, R.-K., Kumar, M., Shin, O.S., Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models. Viruses, 10(72), 2018 https://doi.org/10.3390/v10020072.
37. Lanko, K., Eggermont, K., Patel, A., Kaptein, S., Delang, L., Verfaillie, C.M., Neyts, J., Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. Antivir. Res. 145 (2017), 82–86 https://doi.org/10.1016/j.antiviral.2017.07.010.
38. Madelain, V., Guedj, J., Mentre, F., Nguyen, T.H.T., Jacquot, F., Oestereich, L., Kadota, T., Yamada, K., Taburet, A.M., De Lamballerie, X., Raoul, H., Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob. Agents Chemother., 61, 2017 https://doi.org/10.1128/AAC.01305-16.
39. Madelain, V., Nguyen, T.H.T., Olivo, A., de Lamballerie, X., Guedj, J., Taburet, A.M., Mentré F., Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin. Pharmacokinet., 2016 https://doi.org/10.1007/s40262-015-0364-1.
40. McCarthy, S.D.S., Majchrzak-Kita, B., Racine, T., Kozlowski, H.N., Baker, D.P., Hoenen, T., Kobinger, G.P., Fish, E.N., Branch, D.R., A rapid screening assay identifies monotherapy with interferon-ß and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus. PLoS Negl. Trop. Dis., 10, 2016 https://doi.org/10.1371/journal.pntd.0004364.
41. MDVI, Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults. NCT02008344. [WWW Document], 2013 https://clinicaltrials.gov/ct2/show/NCT02008344.
42. Mendenhall, M., Russell, A., Juelich, T., Messina, E.L., Smee, D.F., Freiberg, A.N., Holbrook, M.R., Furuta, Y., de la Torre, J.-C., Nunberg, J.H., Gowen, B.B., T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55 (2011), 782–787 https://doi.org/10.1128/AAC.01219-10.
43. Mendenhall, M., Russell, A., Smee, D.F., Hall, J.O., Skirpstunas, R., Furuta, Y., Gowen, B.B., Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl. Trop. Dis. 5 (2011), 1–10 https://doi.org/10.1371/journal.pntd.0001342.
44. Mentré F., Taburet, A.-M., Guedj, J., Anglaret, X., Keïta, S., de Lamballerie, X., Malvy, D., Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis. 15 (2015), 150–151 https://doi.org/10.1016/S1473-3099(14)71047-3.
45. Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smee, D.F., Christensen, A.J., Furuta, Y., Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antivir. Res. 80 (2008), 377–379 https://doi.org/10.1016/j.antiviral.2008.07.009.
46. Naesens, L., Guddat, L.W., Keough, D.T., van Kuilenburg, A.B.P., Meijer, J., Vande Voorde, J., Balzarini, J., Role of human hypoxanthine Guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol. Pharmacol. 84 (2013), 615–629 https://doi.org/10.1124/mol.113.087247.
47. Nagata, T., Lefor, A.K., Hasegawa, M., Ishii, M., Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med. Public Health Prep. 9 (2015), 79–81 https://doi.org/10.1017/dmp.2014.151.
48. Nguyen, T.H.T., Guedj, J., Anglaret, X., Laouénan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., Rodallec, A., Piorkowski, G., Carazo, S., Conde, M.N., Gala, J.L., Bore, J.A., Carbonnelle, C., Jacquot, F., Raoul, H., Malvy, D., de Lamballerie, X., Mentré F., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis., 11, 2017 e0005389 https://doi.org/10.1371/journal.pntd.0005389.
49. Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., Günther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105 (2014), 17–21 https://doi.org/10.1016/j.antiviral.2014.02.014.
50. Oestereich, L., Rieger, T., Lüdtke, A., Ruibal, P., Wurr, S., Pallasch, E., Bockholt, S., Krasemann, S., Muñoz-Fontela, C., Günther, S., Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever. J. Infect. Dis. 213 (2016), 934–938 https://doi.org/10.1093/infdis/jiv522.
51. Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Ölschläger, S., Günther, S., Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl. Trop. Dis., 8, 2014 https://doi.org/10.1371/journal.pntd.0002804.
52. Pires de Mello, C.P., Tao, X., Kim, T.H., Bulitta, J.B., Rodriquez, J.L., Pomeroy, J.J., Brown, A.N., Zika virus (ZIKV) replication is substantially inhibited by novel favipiravir and interferon-alpha combination regimens. Antimicrob. Agents Chemother. AAC, 2017 01983–17 https://doi.org/10.1128/AAC.01983-17.
53. Raabe, V.N., Kann, G., Ribner, B.S., Andres, A.M., Varkey, J.B., Mehta, A.K., Lyon, G.M., Vanairsdale, S., Faber, K., Becker, S., Eickmann, M., Strecker, T., Brown, S., Patel, K., De Leuw, P., Schuettfort, G., Stephan, C., Rabenau, H., Klena, J.D., Rollin, P.E., McElroy, A., Ströher, U., Nichol, S., Kraft, C.S., Wolf, T., Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever. Clin. Infect. Dis. 65 (2017), 855–859 https://doi.org/10.1093/cid/cix406.
54. Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Nascimento, M.S.J., Neyts, J., Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 424 (2012), 777–780 https://doi.org/10.1016/j.bbrc.2012.07.034.
55. Rocha-Pereira, J., Nascimento, M.S.J., Ma, Q., Hilgenfeld, R., Neyts, J., Jochmansb, D., The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob. Agents Chemother. 58 (2014), 4675–4681 https://doi.org/10.1128/AAC.02546-13.
56. Rocha-Pereira, J., Van Dycke, J., Neyts, J., Treatment with a nucleoside polymerase inhibitor reduces shedding of murine norovirus in stool to undetectable levels without emergence of drug-resistant variants. Antimicrob. Agents Chemother. 60 (2016), 1907–1911 https://doi.org/10.1128/AAC.02198-15.
57. Safronetz, D., Falzarano, D., Scott, D.P., Furuta, Y., Feldmann, H., Gowen, B.B., Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob. Agents Chemother. 57 (2013), 4673–4680 https://doi.org/10.1128/AAC.00886-13.
58. Safronetz, D., Rosenke, K., Westover, J.B., Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J., Saturday, G., Komeno, T., Geisbert, T.W., Feldmann, H., Gowen, B.B., The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep., 5, 2015 https://doi.org/10.1038/srep14775.
59. Sakamoto, K., Ohashi, S., Yamazoe, R., Takahashi, K., Furuta, Y., The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105. International Control of Foot-and-Mouth Disease: Tools, Trends and Perspectives, 2006. Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease, 15-21 October, Paphos, Cyprus Ap, 2006, 414–420 Appendix 64.
60. Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., Furuta, Y., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 57 (2013), 5202–5208 https://doi.org/10.1128/AAC.00649-13.
61. Scharton, D., Bailey, K.W., Vest, Z., Westover, J.B., Kumaki, Y., Van Wettere, A., Furuta, Y., Gowen, B.B., Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir. Res. 104 (2014), 84–92 https://doi.org/10.1016/j.antiviral.2014.01.016.
62. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., Danel, C., Carazo, S., Conde, M.N., Gala, J.L., Colin, G., Savini, H., Bore, J.A., Le Marcis, F., Koundouno, F.R., Petitjean, F., Lamah, M.C., Diederich, S., Tounkara, A., Poelart, G., Berbain, E., Dindart, J.M., Duraffour, S., Lefevre, A., Leno, T., Peyrouset, O., Irenge, L., Bangoura, N., Palich, R., Hinzmann, J., Kraus, A., Barry, T.S., Berette, S., Bongono, A., Camara, M.S., Chanfreau Munoz, V., Doumbouya, L., Harouna, S., Kighoma, P.M., Koundouno, F.R., Lolamou, R., Loua, C.M., Massala, V., Moumouni, K., Provost, C., Samake, N., Sekou, C., Soumah, A., Arnould, I., Komano, M.S., Gustin, L., Berutto, C., Camara, D., Camara, F.S., Colpaert, J., Delamou, L., Jansson, L., Kourouma, E., Loua, M., Malme, K., Manfrin, E., Maomou, A., Milinouno, A., Ombelet, S., Sidiboun, A.Y., Verreckt, I., Yombouno, P., Bocquin, A., Carbonnelle, C., Carmoi, T., Frange, P., Mely, S., Nguyen, V.K., Pannetier, D., Taburet, A.M., Treluyer, J.M., Kolie, J., Moh, R., Gonzalez, M.C., Kuisma, E., Liedigk, B., Ngabo, D., Rudolf, M., Thom, R., Kerber, R., Gabriel, M., Di Caro, A., Wölfel, R., Badir, J., Bentahir, M., Deccache, Y., Dumont, C., Durant, J.F., El Bakkouri, K., Gasasira Uwamahoro, M., Smits, B., Toufik, N., Van Cauwenberghe, S., Ezzedine, K., Dortenzio, E., Pizarro, L., Etienne, A., Guedj, J., Fizet, A., Barte de Sainte Fare, E., Murgue, B., Tran-Minh, T., Rapp, C., Piguet, P., Poncin, M., Draguez, B., Allaford Duverger, T., Barbe, S., Baret, G., Defourny, I., Carroll, M., Raoul, H., Augier, A., Eholie, S.P., Yazdanpanah, Y., Levy-Marchal, C., Antierrens, A., Van Herp, M., Günther, S., de Lamballerie, X., Keïta, S., Mentre, F., Anglaret, X., Malvy, D., Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med., 13, 2016, e1001967 https://doi.org/10.1371/journal.pmed.1001967.
63. Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104 (2014), 153–155 https://doi.org/10.1016/j.antiviral.2014.01.012.
64. Sun, L., Meijer, A., Froeyen, M., Zhang, L., Thibaut, H.J., Baggen, J., George, S., Vernachio, J., Van Kuppeveld, F.J.M., Leyssen, P., Hilgenfeld, R., Neyts, J., Delang, L., Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 59 (2015), 7782–7785 https://doi.org/10.1128/AAC.01375-15.
65. Takashita, E., Ejima, M., Ogawa, R., Fujisaki, S., Neumann, G., Furuta, Y., Kawaoka, Y., Tashiro, M., Odagiri, T., Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antivir. Res. 132 (2016), 170–177 https://doi.org/10.1016/j.antiviral.2016.06.007.
66. Tani, H., Fukuma, A., Fukushi, S., Taniguchi, S., Yoshikawa, T., Iwata-Yoshikawa, N., Sato, Y., Suzuki, T., Nagata, N., Hasegawa, H., Kawai, Y., Uda, A., Morikawa, S., Shimojima, M., Watanabe, H., Saijo, M., Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere 1 (2016), 1–11 https://doi.org/10.1128/mSphere.00061-15.
67. Tokunaga, T., Yamamoto, Y., Sakai, M., Tomonaga, K., Honda, T., Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Antivir. Res. 143 (2017), 237–245 https://doi.org/10.1016/j.antiviral.2017.04.018.
68. Vanderlinden, E., Huchting, J., Meier, C., Naesens, L., Successful design of ribonucleoside Di- and triphosphate prodrugs to improve the anti-influenza virus activity of T-705 and its analogue T-1105. International Conference on Antiviral Research, 2017, Elsevier, Atlanta.
69. Vanderlinden, E., Vrancken, B., Houdt, Van, J., Rajwanshi, V.K., Gillemot, S., Andrei, G., Lemey, P., Naesens, L., Distinct Effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA. Synth. Antimicrob. Agents Chemother. 60 (2016), 6679–6691 https://doi.org/10.1128/AAC.01156-16.
70. Wang, G., Wan, J., Hu, Y., Wu, X., Prhavc, M., Dyatkina, N., Rajwanshi, V.K., Smith, D.B., Jekle, A., Kinkade, A., Symons, J.A., Jin, Z., Deval, J., Zhang, Q., Tam, Y., Chanda, S., Blatt, L., Beigelman, L., Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-Nucleosides as favipiravir (T-705). Analog. J. Med. Chem. 59 (2016), 4611–4624 https://doi.org/10.1021/acs.jmedchem.5b01933.
71. Wang, Y., Li, G., Yuan, S., Gao, Q., Lan, K., Altmeyer, R., Zou, G., In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob. Agents Chemother. 60 (2016), 5357–5367 https://doi.org/10.1128/AAC.01073-16.
72. Welch, S.R., Scholte, F.E.M., Flint, M., Chatterjee, P., Nichol, S.T., Bergeron, É., Spiropoulou, C.F., Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antivir. Res. 147 (2017), 91–99 https://doi.org/10.1016/j.antiviral.2017.10.008.
73. Westover, J.B., Sefing, E.J., Bailey, K.W., Van Wettere, A.J., Jung, K.H., Dagley, A., Wandersee, L., Downs, B., Smee, D.F., Furuta, Y., Bray, M., Gowen, B.B., Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antivir. Res. 126 (2016), 62–68 https://doi.org/10.1016/j.antiviral.2015.12.006.
74. Yamada, K., Noguchi, K., Komeno, T., Furuta, Y., Nishizono, A., Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis. J. Infect. Dis. 213 (2016), 1253–1261 https://doi.org/10.1093/infdis/jiv586.
75. Zhang, T., Zhai, M., Ji, J., Zhang, J., Tian, Y., Liu, X., Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies. Bioorg. Med. Chem. Lett. 27 (2017), 2364–2368 https://doi.org/10.1016/j.bmcl.2017.04.028.
76. Zmurko, J., Marques, R.E., Schols, D., Verbeken, E., Kaptein, S.J.F., Neyts, J., The viral polymerase inhibitor 7-deaza-2’-C-methyladenosine is a potent inhibitor of in vitro zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis., 2016 https://doi.org/10.1371/journal.pntd.0004695.